Introduced
by
To allow retroactive product liability lawsuits against drug companies for drugs that have been approved by the U.S. Food and Drug Administration (FDA), contingent on House Bill 6225 becoming law. HB 6225 would repeal a 1996 ban on such lawsuits unless the company committed malfeasance in the drug approval process. The bill would authorize a three year window to file a suit based on a complaint against a drug company going back to when the ban was enacted, but only if the ban is repealed.
Referred to the Committee on Judiciary
